We recorded net sales of 1.473 billion USD in Q1, up 25.5% year-on-year at constant currency. Read more about our progress in the press release: https://t.co/zFBRW2wusD
#AdvancingDermatology#Q1results $GALD
Galderma receives U.S. FDA approval of Differin® Epiduo® Acne Gel for over-the-counter use, expanding access to a dermatologist-recommended, prescription-strength acne treatment for ages 12+.
Read more: https://t.co/PExEVUwIvl
#ForUSAudiences#DifferinEpiduo#AdvancingDermatology
Our Q1 2026 trading update call will take place today, Thursday 23, at 3:30 PM CET. We invite investors to join: https://t.co/utlWOVQkOB.
A recording will be made available after the event.
#AdvancingDermatology#Q1results $GALD
Galderma introduces ALASTIN’s Regenerating Skin Nectar with TriHex+™, the newest innovation from Alastin, a leader in peptide-based regenerative skincare.
https://t.co/WI0BKxc6e2
New interim data from two investigator‑initiated studies, proudly supported by Galderma, highlight the role of Sculptra® and Restylane® in addressing aesthetic changes associated with weight loss medications and menopause.
Read more: https://t.co/tWNZdLj5ux
At the @AADskin meeting, 22 abstracts across Therapeutic Dermatology, Injectable Aesthetics and Dermatological Skincare, including late-breaking data in atopic dermatitis, will be presented. #AAD2026
https://t.co/59uLHJsbXW
Galderma receives U.S. FDA approval for Restylane® Contour™ for the correction of temple hollowing, expanding its use beyond cheek augmentation and midface contour deficiencies to support facial balance and harmony.
Read more: https://t.co/V6TWRHra4R
#SkinSciencebyGalderma
At #AMWC2026, Galderma will showcase data across Sculptra®, Restylane® and other injectable aesthetics products highlighting our holistic, future focused approach to aesthetics innovation.
https://t.co/WNJ5wkrjdX
#AdvancingDermatology#SkinSciencebyGalderma
Galderma unveils #Cetaphil AM/PM Antioxidant Serums — a science-driven defense + recovery system designed for sensitive skin. Powered by Gallic-AOX Power™ Technology, delivering greater antioxidant efficacy than Vitamin C with visible results in 7 days.
https://t.co/pMnMSe4ZXZ
Our FY 2025 trading update call for investors takes place today, Thursday 5 March at 2 PM CET. Join live or watch the recording to learn about our record-breaking performance: https://t.co/utlWOVQkOB.
#AdvancingDermatology#FYResults2025 $GALD
FY 2025 results: Galderma achieved record net sales of 5.207 billion USD, surpassing annual sales of 5 billion USD for the first time, growing 17.7% year-on-year at constant currency. Read more: https://t.co/UVsdfm05C1
#AdvancingDermatology#FYResults2025 $GALD
Beauty x Medicine returns with special guest Nicolas Hieronimus, CEO of L’Oréal. His four decades in the beauty industry have shown Nicolas that beauty isn’t just about meeting needs, but about “making dreams come true.
Watch the full episode: https://t.co/79OnmcgZq9
We are presenting new data on the long-term efficacy and safety of our treatment for prurigo nodularis for up to three years at 2026 Winter Clinical™ Miami. Learn more: https://t.co/rzOLyp4jAO
#AdvancingDermatology#SkinSciencebyGalderma#ForInvestors
Galderma secures approval in the EU, U.S., and Canada for its next-generation Restylane® syringe.
Developed with practitioners to enhance ergonomics and injection control, this state-of-the art syringe supports consistent results.
Read more: https://t.co/jOlOq4ar2P
We are pleased to announce the appointment of Luigi La Corte as CFO. He joins us with 30 years of financial leadership in healthcare and consumer businesses, and succeeds Thomas Dittrich.
Read more: https://t.co/YrSiAnZ3Dd
#AdvancingDermatology
We’re uncovering stories from nine real and diverse patients. See how Sculptra® continues to prove its versatility as a regenerative treatment.
Learn more: https://t.co/n3AMC7MPoi
#AdvancingDermatology#Sculptra